Laertty Garcia de Sousa Cabral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laertty Garcia de Sousa Cabral has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Durvanei Augusto Maria
Faculty of Medicine, University of São Paulo, Brazil
9 shared publications - Jean-Luc Poyet
INSERM UMRS1342—CNRS EMR8000, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, 75010 Paris, France
7 shared publications Durvanei Augusto Maria
6 shared publicationsMonique Gonçalves Alves
Faculty of Medicine, University of Sao Paulo, FMUSP, Sao Paulo, Brazil; Laboratory of Development and Innovation, Butantan Institute, Sao Paulo, Brazil
6 shared publications- Cyntia Silva Oliveira
Butantan Institute, 1500 Vital Brazil Avenue, São Paulo 05503-900, SP, Brazil
4 shared publications Rosa Andrea Nogueira Laiso
4 shared publications
Latest Publications
- Open Access
Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy
Melanoma is an aggressive skin cancer that continues to present major therapeutic difficulties. Although targeted drugs and immune checkpoint inhibitors have improved outcomes, resistance and treatment-related toxicity limit long-term benefit. In recent years, nanotechnology has been explored as a way to improve how drugs are delivered and to achieve greater tumor selectivity. Among available nanocarriers, liposomes have attracted particular interest. Built from lipid bilayers, they can carry both hydrophilic and hydrophobic molecules, and they are generally well tolerated. Importantly, their surface can be modified with polymers or targeting ligands to direct the carrier more selectively to melanoma cells. Experimental models show that liposomal drug formulations can increase concentrations in tumor tissue while limiting distribution to healthy organs. They have also been used successfully to combine different types of agents, chemotherapies, immunomodulators, and nucleic acids, within a single delivery system. These findings suggest genuine potential to address several of the shortcomings of conventional treatments. Although translation to the clinic is slowed by challenges such as formulation stability and large-scale production, liposomes represent an important step toward safer and more effective melanoma therapy within the broader field of oncologic nanotechnology.
Open AccessNanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy
Melanoma is an aggressive skin cancer that continues to present major therapeutic difficulties. Although targeted drugs and immune checkpoint inhibitors have improved outcomes, resistance and treatment-related toxicity limit long-term benefit. In recent years, nanotechnology has been explored as a way to improve how drugs are delivered and to achieve greater tumor selectivity. Among available nanocarriers, liposomes have attracted particular interest. Built from lipid bilayers, they can carry both hydrophilic and hydrophobic molecules, and they are generally well tolerated. Importantly, their surface can be modified with polymers or targeting ligands to direct the carrier more selectively to melanoma cells. Experimental models show that liposomal drug formulations can increase concentrations in tumor tissue while limiting distribution to healthy organs. They have also been used successfully to combine different types of agents, chemotherapies, immunomodulators, and nucleic acids, within a single delivery system. These findings suggest genuine potential to address several of the shortcomings of conventional treatments. Although translation to the clinic is slowed by challenges such as formulation stability and large-scale production, liposomes represent an important step toward safer and more effective melanoma therapy within the broader field of oncologic nanotechnology.
- Open Access
Evaluation of the Antitumor and Antiproliferative Potential of Synthetic Peptides Derived from IsCT1, Associated with Cisplatin, in Squamous Cell Carcinoma of the Oral Cavity
Head and neck squamous cell carcinoma (SCC), particularly in the oral cavity, is among the most prevalent and lethal forms of cancer globally. Current therapeutic strategies, predominantly involving cisplatin, face challenges like chemoresistance and toxicity to normal cells, justifying the exploration of new approaches. This study evaluates the antitumor, antiproliferative, and immunomodulatory potential of a synthetic peptide derived from IsCT1 (Isalo scorpion cytotoxic peptide), named AC-AFPK-IsCT1, in combination with cisplatin in oral squamous cell carcinoma cellular models. Tumor and normal cells were treated with varying concentrations of cisplatin and peptide, and the cytotoxicity was measured through an MTT assay, while apoptosis and cell cycle alterations were assessed via flow cytometry. Interestingly, the combination of AC-AFPK-IsCT1 with cisplatin exhibited higher specificity for tumor cells, significantly reducing IC50 values compared to cisplatin used as a single agent. Moreover, the combination treatment induced pronounced S-phase cell cycle arrest and enhanced apoptotic activity, evidenced by the upregulation of caspase-3, caspase-8, and p53, while maintaining low toxicity in normal fibroblast cells. The peptide also modulated the mitochondrial membrane potential, further contributing to the activation of intrinsic apoptotic pathways. The data suggest that AC-AFPK-IsCT1 potentiates the antitumor effects of cisplatin by engaging both intrinsic and extrinsic apoptotic pathways while preserving normal cell viability. These findings underscore the potential of combining cisplatin with AC-AFPK-IsCT1 as a promising therapeutic strategy for improving the efficacy of chemotherapy in SCC, reducing systemic toxicity, and overcoming chemoresistance.
Open AccessEvaluation of the Antitumor and Antiproliferative Potential of Synthetic Peptides Derived from IsCT1, Associated with Cisplatin, in Squamous Cell Carcinoma of the Oral Cavity
Head and neck squamous cell carcinoma (SCC), particularly in the oral cavity, is among the most prevalent and lethal forms of cancer globally. Current therapeutic strategies, predominantly involving cisplatin, face challenges like chemoresistance and toxicity to normal cells, justifying the exploration of new approaches. This study evaluates the antitumor, antiproliferative, and immunomodulatory potential of a synthetic peptide derived from IsCT1 (Isalo scorpion cytotoxic peptide), named AC-AFPK-IsCT1, in combination with cisplatin in oral squamous cell carcinoma cellular models. Tumor and normal cells were treated with varying concentrations of cisplatin and peptide, and the cytotoxicity was measured through an MTT assay, while apoptosis and cell cycle alterations were assessed via flow cytometry. Interestingly, the combination of AC-AFPK-IsCT1 with cisplatin exhibited higher specificity for tumor cells, significantly reducing IC50 values compared to cisplatin used as a single agent. Moreover, the combination treatment induced pronounced S-phase cell cycle arrest and enhanced apoptotic activity, evidenced by the upregulation of caspase-3, caspase-8, and p53, while maintaining low toxicity in normal fibroblast cells. The peptide also modulated the mitochondrial membrane potential, further contributing to the activation of intrinsic apoptotic pathways. The data suggest that AC-AFPK-IsCT1 potentiates the antitumor effects of cisplatin by engaging both intrinsic and extrinsic apoptotic pathways while preserving normal cell viability. These findings underscore the potential of combining cisplatin with AC-AFPK-IsCT1 as a promising therapeutic strategy for improving the efficacy of chemotherapy in SCC, reducing systemic toxicity, and overcoming chemoresistance.
- Top Cited PapersOpen Access
- 25 April 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (5) , 621
Molecular Mechanisms in the Carcinogenesis of Oral Squamous Cell Carcinoma: A Literature Review
The tumor microenvironment (TME) plays a crucial role in the development, progression, and metastasis of oral squamous cell carcinoma (OSCC). The TME comprises various cellular and acellular components, including immune cells, stromal cells, cytokines, extracellular matrix, and the oral microbiome, all of which dynamically interact with tumor cells to influence their behavior. Immunosuppression is a key feature of the OSCC TME, with regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) contributing to an environment that allows tumor cells to evade immune surveillance and supports angiogenesis. The oral microbiome also plays a pivotal role in OSCC pathogenesis, as dysbiosis, or imbalances in the microbiota, can lead to chronic inflammation, which promotes carcinogenesis through the production of pro-inflammatory cytokines and reactive oxygen species (ROS). Pathogens like Porphyromonas gingivalis and Fusobacterium nucleatum have, hence, been implicated in OSCC-driven tumor progression, as they induce inflammation, activate oncogenic pathways, and modulate immune responses. In this review, we discuss how the interplay between immunosuppression and microbiome-driven inflammation creates a tumor-promoting environment in OSCC, leading to treatment resistance and poor patient outcomes, and explore the potential therapeutic implication of a better understanding of OSCC etiology and molecular changes.
- 25 April 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (5) , 621
Top Cited PapersOpen AccessMolecular Mechanisms in the Carcinogenesis of Oral Squamous Cell Carcinoma: A Literature Review
The tumor microenvironment (TME) plays a crucial role in the development, progression, and metastasis of oral squamous cell carcinoma (OSCC). The TME comprises various cellular and acellular components, including immune cells, stromal cells, cytokines, extracellular matrix, and the oral microbiome, all of which dynamically interact with tumor cells to influence their behavior. Immunosuppression is a key feature of the OSCC TME, with regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) contributing to an environment that allows tumor cells to evade immune surveillance and supports angiogenesis. The oral microbiome also plays a pivotal role in OSCC pathogenesis, as dysbiosis, or imbalances in the microbiota, can lead to chronic inflammation, which promotes carcinogenesis through the production of pro-inflammatory cytokines and reactive oxygen species (ROS). Pathogens like Porphyromonas gingivalis and Fusobacterium nucleatum have, hence, been implicated in OSCC-driven tumor progression, as they induce inflammation, activate oncogenic pathways, and modulate immune responses. In this review, we discuss how the interplay between immunosuppression and microbiome-driven inflammation creates a tumor-promoting environment in OSCC, leading to treatment resistance and poor patient outcomes, and explore the potential therapeutic implication of a better understanding of OSCC etiology and molecular changes.
- Open Access
- 1 January 2025
- Published by ALIES in Biomedical and Biopharmaceutical Research
- Vol. 22 (1) , 106-118
Exploiting the Potential of Ankistrodesmus braunii Polysaccharides: In Vitro Antioxidant Activity and In Vivo Cutaneous Biocompatibility
Current demands for sustainable cosmetic sources containing naturally derived compounds have led to extensive research for promising microalgae strains for large-scale cultivation. Given the enormous variety of microalgae strains, as well as their diverse cosmetic potential, here, we cultivated Ankistrodesmus braunii in tubular photobioreactors to extract polysaccharides (PSs) aiming their incorporation into a dermocosmetic prototype gel. In vitro antioxidant activity was determined by the DPPH• (2,2-diphenyl-1-picrylhydrazyl) assay, and in vivo experiments were performed on participants, measuring skin superficial (SK) hydration and transepidermal water loss (TEWL) to determine cutaneous biocompatibility, i.e., the PS safety. A. braunii aqueous PS had superior performance through the DPPH• test, thus, it was incorporated in a gel sample, and its safety profile was established by the cutaneous biocompatibility assay. The biocompatibility of the samples was confirmed by the SK hydration and TEWL results, which were not affected after the application of the gels. Our results suggested not only the biocompatibility of the microalgae PS dermocosmetic, but also the in vitro antioxidant potential, confirming the viability of this material as a new ingredient in cosmetic formulations.
- 1 January 2025
- Published by ALIES in Biomedical and Biopharmaceutical Research
- Vol. 22 (1) , 106-118
Open AccessExploiting the Potential of Ankistrodesmus braunii Polysaccharides: In Vitro Antioxidant Activity and In Vivo Cutaneous Biocompatibility
Current demands for sustainable cosmetic sources containing naturally derived compounds have led to extensive research for promising microalgae strains for large-scale cultivation. Given the enormous variety of microalgae strains, as well as their diverse cosmetic potential, here, we cultivated Ankistrodesmus braunii in tubular photobioreactors to extract polysaccharides (PSs) aiming their incorporation into a dermocosmetic prototype gel. In vitro antioxidant activity was determined by the DPPH• (2,2-diphenyl-1-picrylhydrazyl) assay, and in vivo experiments were performed on participants, measuring skin superficial (SK) hydration and transepidermal water loss (TEWL) to determine cutaneous biocompatibility, i.e., the PS safety. A. braunii aqueous PS had superior performance through the DPPH• test, thus, it was incorporated in a gel sample, and its safety profile was established by the cutaneous biocompatibility assay. The biocompatibility of the samples was confirmed by the SK hydration and TEWL results, which were not affected after the application of the gels. Our results suggested not only the biocompatibility of the microalgae PS dermocosmetic, but also the in vitro antioxidant potential, confirming the viability of this material as a new ingredient in cosmetic formulations.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista Caatinga
- Vol. 38, e11873
Genetic variability of wild yellow plum (Ximenia americana L.) based on rapd markers
Several ethnobotanical studies highlighted the importance of yellow plum as a useful plant species in the Brazilian Northeast region. In order to domesticate and incorporate a native species in production systems it is necessary to obtain information on its development and genetic variation. This work aimed to analyze the genetic variability of individuals of X. americana, accessed by Random Amplified Polymorphic DNA (RAPD) molecular markers. 26 genotypes of X. americana, randomly collected at the private reserve Campo das Emas Farm located in the Caturité City, Paraíba State, Brazil, were used in the study. Through the RAPD technique it was possible to assess the genetic variations among native genotypes within a wild plum population. Based on Sokal and Rohlf dissimilarity coefficient it was possible to form four distinct groups using the UPGMA method. The Cophenetic Correlation Coefficient was 0.83, revealing variability in the consistency of the cluster pattern. The genotypes of X. americana have genetic diversity detected by RAPD markers, which have shown to be efficient in characterizing individuals. Genotypes 4, 8, 9, 11, 13, 14, 15, 16, 18, 21, 24, and 25 are the most divergent and should be used in conservation strategies and breeding programs.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista Caatinga
- Vol. 38, e11873
Open AccessGenetic variability of wild yellow plum (Ximenia americana L.) based on rapd markers
Several ethnobotanical studies highlighted the importance of yellow plum as a useful plant species in the Brazilian Northeast region. In order to domesticate and incorporate a native species in production systems it is necessary to obtain information on its development and genetic variation. This work aimed to analyze the genetic variability of individuals of X. americana, accessed by Random Amplified Polymorphic DNA (RAPD) molecular markers. 26 genotypes of X. americana, randomly collected at the private reserve Campo das Emas Farm located in the Caturité City, Paraíba State, Brazil, were used in the study. Through the RAPD technique it was possible to assess the genetic variations among native genotypes within a wild plum population. Based on Sokal and Rohlf dissimilarity coefficient it was possible to form four distinct groups using the UPGMA method. The Cophenetic Correlation Coefficient was 0.83, revealing variability in the consistency of the cluster pattern. The genotypes of X. americana have genetic diversity detected by RAPD markers, which have shown to be efficient in characterizing individuals. Genotypes 4, 8, 9, 11, 13, 14, 15, 16, 18, 21, 24, and 25 are the most divergent and should be used in conservation strategies and breeding programs.
- Open Access
- 9 December 2024
- Published by MDPI AG in Preprints.org
Exploiting the Potential of Ankistrodesmus braunii Polysaccharides: A Focus on Cutaneous Biocompatibility
Current demands for sustainable cosmetic sources containing naturally derived compounds have led to extensive research for promising microalgae strains for large-scale cultivation. Given the enormous variety of microalgae strains, as well as their diverse cosmetic potential, here, we cultivated Ankistrodesmus braunii in tubular photobioreactors to extract polysaccharides (PSs) aiming their incorporation into a dermocosmetic prototype gel. In vitro antioxidant activity was determined by the DPPH• (2,2-diphenyl-1-picrylhydrazyl) assay, and the in vivo experiments were performed on participants., being the skin superficial (SK) hydration and transepidermal water loss (TEWL) measured to determine cutaneous biocompatibility, i.e., the PS safety. A. braunii aqueous PS had superior performance through the DPPH• test, thus, it was incorporated in a gel prototype, and its safety profile was established by the cutaneous biocompatibility assay. The biocompatibility of the samples was confirmed by the SK hydration and TEWL results, which were not affected after the application of the gels. Our results suggested not only the biocompatibility of the microalgae PS dermocosmetic, but also the in vitro antioxidant potential, confirming this material's conceivable as a new ingredient in cosmetic formulations.
- 9 December 2024
- Published by MDPI AG in Preprints.org
Open AccessExploiting the Potential of Ankistrodesmus braunii Polysaccharides: A Focus on Cutaneous Biocompatibility
Current demands for sustainable cosmetic sources containing naturally derived compounds have led to extensive research for promising microalgae strains for large-scale cultivation. Given the enormous variety of microalgae strains, as well as their diverse cosmetic potential, here, we cultivated Ankistrodesmus braunii in tubular photobioreactors to extract polysaccharides (PSs) aiming their incorporation into a dermocosmetic prototype gel. In vitro antioxidant activity was determined by the DPPH• (2,2-diphenyl-1-picrylhydrazyl) assay, and the in vivo experiments were performed on participants., being the skin superficial (SK) hydration and transepidermal water loss (TEWL) measured to determine cutaneous biocompatibility, i.e., the PS safety. A. braunii aqueous PS had superior performance through the DPPH• test, thus, it was incorporated in a gel prototype, and its safety profile was established by the cutaneous biocompatibility assay. The biocompatibility of the samples was confirmed by the SK hydration and TEWL results, which were not affected after the application of the gels. Our results suggested not only the biocompatibility of the microalgae PS dermocosmetic, but also the in vitro antioxidant potential, confirming this material's conceivable as a new ingredient in cosmetic formulations.
- Open Access
Antitumoral and Antiproliferative Potential of Synthetic Derivatives of Scorpion Peptide IsCT1 in an Oral Cavity Squamous Carcinoma Model
The oral cavity is a frequent site for head and neck cancers, which rank as the sixth most common cancer globally, with a 5-year survival rate slightly over 50%. Current treatments are limited, and resistance to therapy remains a significant clinical obstacle. IsCT1, a membrane-active peptide derived from the venom of the scorpion Opisthacanthus madagascariensis, has shown antitumor effects in various cancer cell lines, including breast cancer and chronic myeloid leukemia. However, its hemolytic action limits its potential therapeutic use. This study aims to assess the antitumor and antiproliferative activities of synthetic peptides derived from IsCT1 (IsCT-P, AC-AFPK-IsCT1, AFPK-IsCT1, AC-KKK-IsCT1, and KKK-IsCT1) in the context of oral squamous cell carcinoma. We evaluated the cytotoxic effects of these peptides on tongue squamous cell carcinoma cells and normal cells, as well as their impact on cell cycle phases, the expression of proliferation markers, modulators of cell death pathways, and mitochondrial potential. Our results indicate that the IsCT1 derivatives IsCT-P and AC-AFPK-IsCT1 possess cytotoxic properties towards squamous cell carcinoma cells, reducing mitochondrial membrane potential and the proliferative index. The treatment of cancer cells with AC-AFPK-IsCT1 led to a positive modulation of pro-apoptotic markers p53 and caspases 3 and 8, a decrease in PCNA and Cyclin D1 expression, and cell cycle arrest in the S phase. Notably, contrary to the parental IsCT1 peptide, AC-AFPK-IsCT1 did not exhibit hemolytic activity or cytotoxicity towards normal cells. Therefore, AC-AFPK-IsCT1 might be a viable therapeutic option for head and neck cancer treatment.
Open AccessAntitumoral and Antiproliferative Potential of Synthetic Derivatives of Scorpion Peptide IsCT1 in an Oral Cavity Squamous Carcinoma Model
The oral cavity is a frequent site for head and neck cancers, which rank as the sixth most common cancer globally, with a 5-year survival rate slightly over 50%. Current treatments are limited, and resistance to therapy remains a significant clinical obstacle. IsCT1, a membrane-active peptide derived from the venom of the scorpion Opisthacanthus madagascariensis, has shown antitumor effects in various cancer cell lines, including breast cancer and chronic myeloid leukemia. However, its hemolytic action limits its potential therapeutic use. This study aims to assess the antitumor and antiproliferative activities of synthetic peptides derived from IsCT1 (IsCT-P, AC-AFPK-IsCT1, AFPK-IsCT1, AC-KKK-IsCT1, and KKK-IsCT1) in the context of oral squamous cell carcinoma. We evaluated the cytotoxic effects of these peptides on tongue squamous cell carcinoma cells and normal cells, as well as their impact on cell cycle phases, the expression of proliferation markers, modulators of cell death pathways, and mitochondrial potential. Our results indicate that the IsCT1 derivatives IsCT-P and AC-AFPK-IsCT1 possess cytotoxic properties towards squamous cell carcinoma cells, reducing mitochondrial membrane potential and the proliferative index. The treatment of cancer cells with AC-AFPK-IsCT1 led to a positive modulation of pro-apoptotic markers p53 and caspases 3 and 8, a decrease in PCNA and Cyclin D1 expression, and cell cycle arrest in the S phase. Notably, contrary to the parental IsCT1 peptide, AC-AFPK-IsCT1 did not exhibit hemolytic activity or cytotoxicity towards normal cells. Therefore, AC-AFPK-IsCT1 might be a viable therapeutic option for head and neck cancer treatment.
- Open Access
- 5 January 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (1) , 527-541
Cytotoxic Effect of Andrographis paniculata Associated with 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cells
Cancer stands out as a major global public health concern and a significant impediment to increasing life expectancy worldwide. Natural bioactives derived from plants are renowned for their efficacy in treating various types of cancer. Andrographis paniculata (Burm.f.) is a well-known plant traditionally employed in diverse medical systems across the globe. The 2-AEH2P monophosphoester, a molecule intricately involved in phospholipid turnover, demonstrates antiproliferative effects across a broad spectrum of cancer types. This study aims to assess the antitumor, antiproliferative, and pharmacological effects of andrographolide at different concentrations, both individually and in conjunction with 2-aminoethyl dihydrogen phosphate. The cytotoxicity of the treatments was evaluated using the colorimetric MTT method, cell cycle phases, mitochondrial electrical potential, and markers expression via flow cytometry, while the pharmacological effects were assessed using SynergyFinder software 3.0. Treatments with A. paniculata, isolated at concentrations of 10%, 30%, and 50% of andrographolide, induced cell death in tumor cells, resulting in a reduction in mitochondrial electrical potential and alterations in cell cycle phases, particularly a decrease in the population of MDA MB-231 cells in the G0/G1 phase. The combination treatments exhibited significant cytotoxicity toward tumor cells, with minimal toxicity observed in normal fibroblast cells FN1. This led to a reduction in mitochondrial electrical potential and cell cycle arrest in the S phase for MDA MB-231 cells. Across all concentrations, the combined treatments demonstrated a synergistic pharmacological effect, underscoring the efficacy of the association. There was a change in the markers involved in cell death, such as p53, caspase 3, Bcl-2, and cytochrome c, suggesting the induction of regulated cell death. Markers associated with progression and proliferation, such as cyclin D1 and p21, corroborate the findings for cytotoxicity and cell cycle arrest.
- 5 January 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (1) , 527-541
Open AccessCytotoxic Effect of Andrographis paniculata Associated with 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cells
Cancer stands out as a major global public health concern and a significant impediment to increasing life expectancy worldwide. Natural bioactives derived from plants are renowned for their efficacy in treating various types of cancer. Andrographis paniculata (Burm.f.) is a well-known plant traditionally employed in diverse medical systems across the globe. The 2-AEH2P monophosphoester, a molecule intricately involved in phospholipid turnover, demonstrates antiproliferative effects across a broad spectrum of cancer types. This study aims to assess the antitumor, antiproliferative, and pharmacological effects of andrographolide at different concentrations, both individually and in conjunction with 2-aminoethyl dihydrogen phosphate. The cytotoxicity of the treatments was evaluated using the colorimetric MTT method, cell cycle phases, mitochondrial electrical potential, and markers expression via flow cytometry, while the pharmacological effects were assessed using SynergyFinder software 3.0. Treatments with A. paniculata, isolated at concentrations of 10%, 30%, and 50% of andrographolide, induced cell death in tumor cells, resulting in a reduction in mitochondrial electrical potential and alterations in cell cycle phases, particularly a decrease in the population of MDA MB-231 cells in the G0/G1 phase. The combination treatments exhibited significant cytotoxicity toward tumor cells, with minimal toxicity observed in normal fibroblast cells FN1. This led to a reduction in mitochondrial electrical potential and cell cycle arrest in the S phase for MDA MB-231 cells. Across all concentrations, the combined treatments demonstrated a synergistic pharmacological effect, underscoring the efficacy of the association. There was a change in the markers involved in cell death, such as p53, caspase 3, Bcl-2, and cytochrome c, suggesting the induction of regulated cell death. Markers associated with progression and proliferation, such as cyclin D1 and p21, corroborate the findings for cytotoxicity and cell cycle arrest.
- Open Access
- 4 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 109
2-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor
The progression and maintenance of cancer characteristics are associated with cellular components linked to the tumor and non-cellular components with pro-tumoral properties. Pharmacological association with antagonists of the cellular components of the tumor, such as anti- and pro-apoptotic drugs, represents a novel adjuvant strategy. In this study, the antiproliferative, pro-apoptotic, and pharmacological effects of the combination of monophosphoester 2-AEH2P with Simvastatin, Coenzyme Q10, the chemotherapeutic drug paclitaxel, and colony-stimulating factor (GM-CSF) were evaluated. Tests were conducted to determine cytotoxic activity using the MTT method, cell cycle phases, and fragmented DNA by flow cytometry, mitochondrial membrane potential, expression of cell markers Bcl2, TNF-α/DR-4, Cytochrome c, caspase 3, and P53, and analysis of drug combination profiles using Synergy Finder 2.0 Software. The results showed a synergistic effect among the combinations, compared to individual treatments with the monophosphoester and other drugs. In addition, there was modulation of marker expression, indicating a pro-apoptotic and immunomodulatory effect of 2-AEH2P. Pharmacological analysis revealed that tumor cells treated with GM-CSF + 2-AEH2P exhibited a synergistic effect, while groups of tumor cells treated with paclitaxel, Coenzyme Q10, and Simvastatin showed additive effects. Furthermore, treatment with the paclitaxel + 2-AEH2P combination (12 h) resulted in a significant reduction in mitochondrial membrane potential. Pharmacological combinations for normal cells did not exhibit deleterious effects compared to mammary carcinomatosis tumor (EAT) cells.
- 4 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 109
Open Access2-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor
The progression and maintenance of cancer characteristics are associated with cellular components linked to the tumor and non-cellular components with pro-tumoral properties. Pharmacological association with antagonists of the cellular components of the tumor, such as anti- and pro-apoptotic drugs, represents a novel adjuvant strategy. In this study, the antiproliferative, pro-apoptotic, and pharmacological effects of the combination of monophosphoester 2-AEH2P with Simvastatin, Coenzyme Q10, the chemotherapeutic drug paclitaxel, and colony-stimulating factor (GM-CSF) were evaluated. Tests were conducted to determine cytotoxic activity using the MTT method, cell cycle phases, and fragmented DNA by flow cytometry, mitochondrial membrane potential, expression of cell markers Bcl2, TNF-α/DR-4, Cytochrome c, caspase 3, and P53, and analysis of drug combination profiles using Synergy Finder 2.0 Software. The results showed a synergistic effect among the combinations, compared to individual treatments with the monophosphoester and other drugs. In addition, there was modulation of marker expression, indicating a pro-apoptotic and immunomodulatory effect of 2-AEH2P. Pharmacological analysis revealed that tumor cells treated with GM-CSF + 2-AEH2P exhibited a synergistic effect, while groups of tumor cells treated with paclitaxel, Coenzyme Q10, and Simvastatin showed additive effects. Furthermore, treatment with the paclitaxel + 2-AEH2P combination (12 h) resulted in a significant reduction in mitochondrial membrane potential. Pharmacological combinations for normal cells did not exhibit deleterious effects compared to mammary carcinomatosis tumor (EAT) cells.
- Open Access
Antiproliferative Modulation and Pro-Apoptotic Effect of BR2 Tumor-Penetrating Peptide Formulation 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cancer
Breast cancer is the most common cancer in women, the so-called “Triple-Negative Breast Cancer” (TNBC) subtype remaining the most challenging to treat, with low tumor-free survival and poor clinical evolution. Therefore, there is a clear medical need for innovative and more efficient treatment options for TNBC. The aim of the present study was to evaluate the potential therapeutic interest of the association of the tumor-penetrating BR2 peptide with monophosphoester 2-aminoethyl dihydrogen phosphate (2-AEH2P), a monophosphoester involved in cell membrane turnover, in TNBC. For that purpose, viability, migration, proliferative capacity, and gene expression analysis of proteins involved in the control of proliferation and apoptosis were evaluated upon treatment of an array of TNBC cells with the BR2 peptide and 2-AEH2P, either separately or combined. Our data showed that, while possessing limited single-agent activity, the 2-AEH2P+BR2 association promoted significant cytotoxicity in TNBC cells but not in normal cells, with reduced proliferative potential and inhibition of cell migration. Mechanically, the 2-AEH2P+BR2 combination promoted an increase in cells expressing p53 caspase 3 and caspase 8, a reduction in cells expressing tumor progression and metastasis markers such as VEGF and PCNA, as well as a reduction in mitochondrial electrical potential. Our results indicate that the combination of the BR2 peptide with 2-AEH2P+BR2 may represent a promising therapeutic strategy in TNBC with potential use in clinical settings.
Open AccessAntiproliferative Modulation and Pro-Apoptotic Effect of BR2 Tumor-Penetrating Peptide Formulation 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cancer
Breast cancer is the most common cancer in women, the so-called “Triple-Negative Breast Cancer” (TNBC) subtype remaining the most challenging to treat, with low tumor-free survival and poor clinical evolution. Therefore, there is a clear medical need for innovative and more efficient treatment options for TNBC. The aim of the present study was to evaluate the potential therapeutic interest of the association of the tumor-penetrating BR2 peptide with monophosphoester 2-aminoethyl dihydrogen phosphate (2-AEH2P), a monophosphoester involved in cell membrane turnover, in TNBC. For that purpose, viability, migration, proliferative capacity, and gene expression analysis of proteins involved in the control of proliferation and apoptosis were evaluated upon treatment of an array of TNBC cells with the BR2 peptide and 2-AEH2P, either separately or combined. Our data showed that, while possessing limited single-agent activity, the 2-AEH2P+BR2 association promoted significant cytotoxicity in TNBC cells but not in normal cells, with reduced proliferative potential and inhibition of cell migration. Mechanically, the 2-AEH2P+BR2 combination promoted an increase in cells expressing p53 caspase 3 and caspase 8, a reduction in cells expressing tumor progression and metastasis markers such as VEGF and PCNA, as well as a reduction in mitochondrial electrical potential. Our results indicate that the combination of the BR2 peptide with 2-AEH2P+BR2 may represent a promising therapeutic strategy in TNBC with potential use in clinical settings.